Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Avelumab + Axitinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Avelumab||Bavencio||MSB0010718C||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 69||Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov).|
|Axitinib||Inlyta||AG-013736|AG013736||KIT Inhibitor 51 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 32||Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||renal cell carcinoma||not applicable||Avelumab + Axitinib||FDA approved||Actionable||In a Phase III trial that supported FDA approval (JAVELIN Renal 101), Inlyta (axitinib) plus Bavencio (avelumab) resulted in a median progression-free survival of 13.8 mo. and an objective response rate of 51.4%, vs. 8.4 mo. and 25.7% with Sutent (sunitinib), respectively in patients with advanced renal cell carcinoma, and at median follow-up 14.3% (63) of patients treated with Inlyta (axitinib) plus Bavencio (avelumab) had died vs. 16.9% (75) with Sutent (sunitinib) (PMID: 30779531; NCT02684006).||detail... 30779531|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02493751||Phase I||Avelumab + Axitinib||A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer||Active, not recruiting||USA||2|
|NCT02912572||Phase II||Avelumab + Talazoparib Avelumab Avelumab + Axitinib||Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer||Recruiting||USA||0|
|NCT02684006||Phase III||Avelumab + Axitinib Sunitinib||A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)||Active, not recruiting||USA | CAN||19|
|NCT03472560||Phase II||Avelumab + Axitinib||A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)||Active, not recruiting||USA||7|
|NCT03990571||Phase II||Avelumab + Axitinib||Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma||Recruiting||USA||0|